KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Short term Debt (2016 - 2025)

Gilead Sciences (GILD) has disclosed Short term Debt for 17 consecutive years, with $2.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt rose 54.66% year-over-year to $2.8 billion, compared with a TTM value of $2.8 billion through Dec 2025, up 54.66%, and an annual FY2025 reading of $2.8 billion, up 54.66% over the prior year.
  • Short term Debt was $2.8 billion for Q4 2025 at Gilead Sciences, roughly flat from $2.8 billion in the prior quarter.
  • Across five years, Short term Debt topped out at $4.0 billion in Q2 2023 and bottomed at $1.0 billion in Q2 2022.
  • Average Short term Debt over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2021.
  • The sharpest move saw Short term Debt soared 295.4% in 2023, then plummeted 55.16% in 2024.
  • Year by year, Short term Debt stood at $1.5 billion in 2021, then skyrocketed by 49.93% to $2.3 billion in 2022, then fell by 20.9% to $1.8 billion in 2023, then rose by 0.95% to $1.8 billion in 2024, then soared by 54.66% to $2.8 billion in 2025.
  • Business Quant data shows Short term Debt for GILD at $2.8 billion in Q4 2025, $2.8 billion in Q3 2025, and $2.8 billion in Q2 2025.